Lv3
384 积分 2024-01-04 加入
STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY
13天前
已完结
Neoadjuvant Chemo-Immunotherapy for Surgically Resectable Non-Small Cell Lung Cancer: Balancing Promise and Pitfalls
13天前
已完结
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial
17天前
已完结
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)
1个月前
已完结
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
2个月前
已完结
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
3个月前
已完结
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
3个月前
已完结
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
7个月前
已完结
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
8个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
8个月前
已完结
皖公网安备34019202002308
